Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 9/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 7/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752779 | 0.83 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6752801 | 0.82 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6752752 | 0.81 | HTR1A (0.76) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6579957 | 0.81 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL9844858 | 0.80 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6751064 | 0.80 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6580134 | 0.79 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL3488017 | 0.79 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6581749 | 0.76 | ADRA1B (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6582012 | 0.75 | ADRA1B (1.00) | HTR1AADRA1BADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706716-B2 | NERVOUS SYSTEM DISORDERS; HYPOTENSIVE AGENTS; INCONTINENCE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-03-16 | — | — | US | disclosed |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | H. LUNDBECK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | HTR1A 67/4885ADRA1B 4/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.